Finance
Getinge Lags Profit Estimates as Uncertainty Curbs Investments in Medical Equipment
Published by Global Banking & Finance Review®
Posted on April 21, 2026
2 min readLast updated: April 21, 2026
Add as preferred source on Google
Quick Summary
Getinge’s Q1 2026 core earnings fell short of expectations due to weak ventilator demand, tariffs, and currency headwinds amid geopolitical uncertainty, though orders rose modestly and the company reaffirmed its 2026 sales guidance.
Getinge Misses Q1 Profit Estimates Amid Medical Equipment Investment Drop
Getinge’s First-Quarter Financial Performance and Market Challenges
Q1 Earnings and Revenue Overview
April 21 (Reuters) - Swedish medical equipment maker Getinge reported a bigger than expected drop in first-quarter core earnings on Tuesday, citing a decline in ventilator sales and lower investments at a time of heightened geopolitical uncertainty.
Impact of Geopolitical Uncertainty and Tariffs
The maker of products for surgery, intensive care and sterilisation has been grappling with higher U.S. import tariffs that squeezed margins and forced it to raise prices of its products, cut costs and adjust supply chains over the past year.
"The investment climate for pharma is impacted by the geopolitical uncertainty," CEO Mattias Perjos said in the quarterly report.
Key Financial Highlights
- Lower investments are mainly reflected in the order intake for the project-based and capital-intense washers, isolators, and sterilizers category, Perjos said
- Quarterly orders rose 3.9% organically, marking a ninth straight quarter of growth
- Adjusted EBITA fell 18% to 824 million Swedish crowns ($90 million) in Q1, versus analysts' consensus of 829 million crowns
- The core profit took a hit of 122 million crowns from currency exchange rates; tariff costs had an impact of 104 million crowns
- Getinge makes more than a third of its sales in the U.S.
- It has shifted higher raw material and tariff costs to customers through price hikes, though their delayed effects forced it to absorb significant costs in the short term
- Getinge confirmed 2026 forecast for organic sales growth of 3% to 5%
Market Outlook and Future Projections
($1 = 9.1556 Swedish crowns)
(Reporting by Marta Frackowiak in Gdansk; Editing by Milla Nissi-Prussak)
Key Takeaways
- •Adjusted EBITA dropped 18% to SEK 824 million, slightly below analysts’ forecast of SEK 829 million, dragged down by currency (SEK 122 million) and tariff impacts (SEK 104 million) (marketscreener.com).
- •Organic quarterly orders rose 3.9%, marking the ninth consecutive quarter of growth, but order intake in capital‑intensive segments like washers and sterilizers weakened due to reduced pharma investments amid geopolitical uncertainty (marketscreener.com).
- •Despite headwinds, Getinge confirmed its 2026 guidance of 3–5% organic sales growth and is navigating margin pressure through price increases, cost management, and supply‑chain adjustments (marketscreener.com).
References
Frequently Asked Questions about Getinge lags profit estimates as uncertainty curbs investments in medical equipment
1Why did Getinge's core earnings decline in Q1?
Getinge's core earnings declined due to a drop in ventilator sales, lower investments in medical equipment, higher US tariffs, and unfavorable currency exchange rates.
2How has Getinge responded to increased costs from US tariffs?
Getinge has raised product prices, cut costs, and adjusted supply chains to manage higher import tariffs and raw material costs.
3What portion of Getinge's sales comes from the US?
More than a third of Getinge's sales are generated in the United States.
